drugset / Trial / NCT02878681
24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of the study is to compare the effect of intravitreal injections of ranibizumab and aflibercept on systemic VEGF levels in DME patients in a detailed time course.
Timeline
- Start
- 2016-09
- Primary completion
- 2017-09
- Completion
- 2017-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |